The inflammatory response to severe traumatic injury results in significant morbidity and mortality. Lymphocytes have recently been identified as critical mediators of the early innate immune response to ischemia-reperfusion injury. Experimental manipulation of lymphocytes following hemorrhagic shock may prevent secondary immunologic injury in surgical and trauma patients. The objective of this study is to evaluate the lymphocyte sequestration agent FTY720 as an immunomodulator following experimental hemorrhagic shock in a swine liver injury model. Yorkshire swine were anesthetized and underwent a grade III liver injury with uncontrolled hemorrhage to induce hemorrhagic shock. Experimental groups were treated with a lymphocyte sequestration agent, FTY720, (n = 9) and compared to a vehicle control group (n = 9). Animals were observed over a 3 day survival period after hemorrhage. Circulating total leukocyte and neutrophil counts were measured. Central lymphocytes were evaluated with mesenteric lymph node and spleen immunohistochemistry (IHC) staining for CD3. Lung tissue infiltrating neutrophils were analyzed with myeloperoxidase (MPO) IHC staining. Relevant immune-related gene expression from liver tissue was quantified using RT-PCR. The overall survival was 22.2% in the vehicle control and 66.7% in the FTY720 groups (p = 0.081), and reperfusion survival (period after hemorrhage) was 25% in the vehicle control and 75% in the FTY720 groups (p = 0.047). CD3+ lymphocytes were significantly increased in mesenteric lymph nodes and spleen in the FTY720 group compared to vehicle control, indicating central lymphocyte sequestration. Lymphocyte disruption significantly decreased circulating and lung tissue infiltrating neutrophils, and decreased expression of liver immune-related gene expression in the FTY720 treated group. There were no observed infectious or wound healing complications. Lymphocyte sequestration with FTY720 improves survival in experimental hemorrhagic shock using a porcine liver injury model. These results support a novel and clinically relevant lymphocyte immunomodulation strategy to ameliorate secondary immune injury in hemorrhagic shock.
References
[1]
Moore FA, Moore EE (2004) Postinjury multiple organ failure. In: Moore EE, Feliciano DV, Mattox KL, editors. New York: McGraw-Hill.
[2]
De AK, Kodys KM, Pellegrini J, Yeh B, Furse RK, et al. (2000) Induction of global anergy rather than inhibitory Th2 lymphokines mediates posttrauma T cell immunodepression. Clin Immunol 96: 52–66.
[3]
Spolarics Z, Siddiqi M, Siegel JH, Garcia ZC, Stein DS, et al. (2003) Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. Crit Care Med 31: 1722–1729.
[4]
Bandyopadhyay G, De A, Laudanski K, Li F, Lentz C, et al. (2007) Negative signaling contributes to T-cell anergy in trauma patients. Crit Care Med 35: 794–801.
[5]
Rabb H, Daniels F, O'Donnell M, Haq M, Saba SR, et al. (2000) Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol 279: F525–531.
[6]
Horie Y, Wolf R, Chervenak RP, Jennings SR, Granger DN (1999) T-lymphocytes contribute to hepatic leukostasis and hypoxic stress induced by gut ischemia-reperfusion. Microcirculation 6: 267–280.
[7]
Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L, et al. (1997) CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 100: 279–289.
[8]
Le Moine O, Louis H, Demols A, Desalle F, Demoor F, et al. (2000) Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology 31: 1266–1274.
[9]
Caldwell CC, Tschoep J, Lentsch AB (2007) Lymphocyte function during hepatic ischemia/reperfusion injury. J Leukoc Biol 82: 457–464.
[10]
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
[11]
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415.
[12]
Rivera J, Proia RL, Olivera A (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8: 753–763.
[13]
Arnaud F, Handrigan M, Hammett M, Philbin N, Rice J, et al. (2006) Coagulation patterns following haemoglobin-based oxygen carrier resuscitation in severe uncontrolled haemorrhagic shock in swine. Transfus Med 16: 290–302.
[14]
Hawksworth JS, Elster EA, Fryer D, Sheppard F, Morthole V, et al. (2009) Evaluation of lyophilized platelets as an infusible hemostatic agent in experimental non-compressible hemorrhage in swine. J Thromb Haemost 7: 1663–1671.
Botha AJ, Moore FA, Moore EE, Sauaia A, Banerjee A, et al. (1995) Early neutrophil sequestration after injury: a pathogenic mechanism for multiple organ failure. J Trauma 39: 411–417.
[17]
Weiss SJ (1989) Tissue destruction by neutrophils. N Engl J Med 320: 365–376.
[18]
Pallister I, Dent C, Topley N (2002) Increased neutrophil migratory activity after major trauma: a factor in the etiology of acute respiratory distress syndrome? Crit Care Med 30: 1717–1721.
[19]
Windsor AC, Mullen PG, Fowler AA, Sugerman HJ (1993) Role of the neutrophil in adult respiratory distress syndrome. Br J Surg 80: 10–17.
[20]
Lenz A, Franklin GA, Cheadle WG (2007) Systemic inflammation after trauma. Injury 38: 1336–1345.
[21]
Harlan JM, Winn RK (2002) Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 30: S214–219.
[22]
Rhee P, Morris J, Durham R, Hauser C, Cipolle M, et al. (2000) Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group. J Trauma 49: 611–619; discussion 619–620.
[23]
Yonekawa K, Harlan JM (2005) Targeting leukocyte integrins in human diseases. J Leukoc Biol 77: 129–140.
[24]
Huang Y, Rabb H, Womer KL (2007) Ischemia-reperfusion and immediate T cell responses. Cell Immunol 248: 4–11.
[25]
Matzinger P (1998) An innate sense of danger. Semin Immunol 10: 399–415.
[26]
Kokura S, Wolf RE, Yoshikawa T, Granger DN, Aw TY (2000) Postanoxic T lymphocyte-endothelial cell interactions induce tumor necrosis factor-alpha production and neutrophil adhesion: role of very late antigen-4/vascular cell adhesion molecule-1. Circ Res 86: 1237–1244.
[27]
Kokura S, Wolf RE, Yoshikawa T, Ichikawa H, Granger DN, et al. (2000) Endothelial cells exposed to anoxia/reoxygenation are hyperadhesive to T-lymphocytes: kinetics and molecular mechanisms. Microcirculation 7: 13–23.
[28]
Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, et al. (2001) Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 108: 1283–1290.
[29]
Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL (1997) The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 100: 1199–1203.
[30]
Brinkmann V, Pinschewer DD, Feng L, Chen S (2001) FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 72: 764–769.
[31]
Brinkmann V, Lynch KR (2002) FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 14: 569–575.
[32]
Brinkmann V, Cyster JG, Hla T (2004) FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 4: 1019–1025.
[33]
Dragun D, Bohler T, Nieminen-Kelha M, Waiser J, Schneider W, et al. (2004) FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. Kidney Int 65: 1076–1083.
[34]
Hawksworth JS, Brown TS, Fryer D, Gage F, Graybill JC, et al. (2009) Lymphocyte Immunomodulation Improves Survival in Experimental Hemorrhagic Shock. Abstract. Journal of Surgical Research 151: 267.
[35]
Peters SL, Alewijnse AE (2007) Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 7: 186–192.
[36]
Zhao Y, Man K, Lo CM, Ng KT, Li XL, et al. (2004) Attenuation of small-for-size liver graft injury by FTY720: significance of cell-survival Akt signaling pathway. Am J Transplant 4: 1399–1407.
[37]
Nugent D, Xu Y (2000) Sphingosine-1-phosphate: characterization of its inhibition of platelet aggregation. Platelets 11: 226–232.
[38]
Koyrakh L, Roman MI, Brinkmann V, Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 5: 529–536.
[39]
Weaver TA, Kirk AD (2007) Alemtuzumab. Transplantation 84: 1545–1547.
